Thomas Gad is Founder, President and Head of Business Development and Strategy. Thomas Gad founded YmAbs in April 2014 inspired by his daughter going through 6 years of treatment overcoming high-risk neuroblastoma receiving break-through cancer immunotherapy at Memorial Sloan Kettering Cancer Center (MSK), and secured executive management and seed capital for inception of the Company. Thomas Gad has more than 12 years industry experience from the pharmaceutical industry, including business development, senior management, financing and licensing negotiations. Thomas Gad has a Bachelor of Science in Business Administration from Pepperdine University, California, USA.
Claus Moller, MD, PhD serves as Chief Executive Officer of the Company. Claus Moller is the Founder of Azanta A/S and was the Chief Executive Officer of Azanta from 2009 to 2015. In addition, Claus Moller has extensive experience in the pharmaceutical and biotechnology industries and was a co-founder of one of the largest European biotech companies, Genmab, in 1999, where he served as Executive Vice President and Chief Operating Officer until 2008. Previous positions include Executive Vice President and Chief Medical and Operating Officer of OXiGENE, Inc., and Medical Director of Synthélabo Scandinavia. Claus Moller received his M.D. and Ph.D. degrees from the University of Copenhagen.
Bo Kruse serves as Chief Financial Officer, Treasurer and Secretary of the Company. Bo Kruse has broad international finance experience, including knowledge of capital markets, accounting and other financing activities. Prior to joining the Company, Bo Kruse was the Chief Financial Officer of the Danish biotech company Azanta from 2009 to 2015. Further, Bo Kruse served as Genmab’s Vice President and Chief Financial Officer from 2005 to 2008 and in a number of other finance positions, including Vice President and Chief Accounting Officer, from 2000 to 2005. During his eight year tenure at Genmab, Bo Kruse was directly involved in several financing rounds, including Genmab’s initial public offering. Bo Kruse has a Master and Bachelors of Science in Commerce from the Copenhagen Business School.
Torben Lund-Hansen, PhD serves as SVP, Head of Technical Operations. Torben Lund-Hansen has substantial experience in antibody process development, commercial manufacturing and global project management from Novo Nordisk A/S, Maxigen A/S and Genmab A/S. At Genmab A/S he served as Senior Vice President, Technical Operations and was responsible for outsourcing of clinical and commercial drug substance and drug product manufacturing. From 2008 to 2009 he was President and Treasurer for Genmab MN Inc., in Minnesota, US. Torben Lund-Hansen has been responsible for compiling technical CMC documentation packages submitted to global regulatory agencies followed by approval and launch of several biologics. Torben Lund-Hansen received his M.Sc. and Ph.D. from the University of Copenhagen.
Steen Lisby, MD, DMSc, serves as SVP, Chief Medical Officer. Steen Lisby received his MD degree from the University of Copenhagen. Steen Lisby has extensive clinical and scientific experience. He is author of over 50 scientific peer-reviewed publications within clinical research and holds a Doctorate of Medical Science also from the University of Copenhagen. Steen Lisby previously worked at GlaxoSmithKline plc and Genmab A/S. In 2015 he was appointed VP, Head of Medical, Genmab A/S. Steen Lisby ended his tenure with Genmab in June 2017.
Joris Wilms, serves as SVP, Chief Operating Officer. Joris Wilms has extensive industry experience in Clinical Development primarily within oncology and hematology indications. He has been responsible for overseeing several first-in-human studies and pivotal clinical trials, leading to the approval of two monoclonal antibodies. Previous positions include VP Clinical Trial Services and Pharmacovigilance at KLIFO A/S, and Associate Director Clinical Development at Genmab A/S. Joris Wilms received his MSc Pharm from the University of Groningen, Netherlands.